Buparlisib
- Generic Name
- Buparlisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21F3N6O2
- CAS Number
- 944396-07-0
- Unique Ingredient Identifier
- 0ZM2Z182GD
- Background
Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients
- Conditions
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT01911325
- Locations
- πΊπΈ
Reliant Medical Group Reliant Medical Group, Worcester, Massachusetts, United States
πΊπΈH. Lee Moffitt Cancer Center & Research Institute H Lee Moffitt, Tampa, Florida, United States
πΊπΈHighlands Oncology Group SC-1, Fayetteville, Arkansas, United States
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT01870726
- Locations
- πΊπΈ
Dana Farber Cancer Institute SC, Boston, Massachusetts, United States
πΊπΈColumbia University Medical Center- New York Presbyterian Dept of Oncology, New York, New York, United States
πΊπΈMemorial Sloan Kettering Cancer Center Neurology, New York, New York, United States
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
- Conditions
- Interventions
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 157
- Registration Number
- NCT01852292
- Locations
- πΊπΈ
Dana Farber Cancer Institute IRB, Boston, Massachusetts, United States
πΊπΈUniversity of N.C. at Chapel Hill Lineberger Comp. Cancer Ctr., Chapel Hill, North Carolina, United States
π¬π§Novartis Investigative Site, Manchester, United Kingdom
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-03-28
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT01820325
- Locations
- πΊπΈ
Northwest Cancer Specialists Compass Oncology -BKM, Portland, Oregon, United States
πͺπΈNovartis Investigative Site, Madrid, Spain
πΊπΈHighlands Oncology Group, Fayetteville, Arkansas, United States
Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-11-01
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 7
- Registration Number
- NCT01719250
- Locations
- πΊπΈ
Mayo Clinic, Rochester, Minnesota, United States
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
- Conditions
- Interventions
- First Posted Date
- 2012-09-26
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT01693614
- Locations
- πΊπΈ
Memorial Sloan Kettering Dept of Onc., New York, New York, United States
πΊπΈMedical University of South Carolina -Hollings Cancer Center Medical Univ of South Carolina, Charleston, South Carolina, United States
πΉπ·Novartis Investigative Site, Samsun, Turkey
Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium
- Conditions
- Interventions
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT01551030
- Locations
- πΊπΈ
Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States
πΊπΈMemorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States
πΊπΈMemorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.